

| | | |
|--|--|------------------------------|
| <p>Informazione Regolamentata n. 20343-18-2026</p> | <p>Data/Ora Inizio Diffusione 2 Luglio 2026 08:00:11</p> | <p>Euronext Growth Milan</p> |
|--|--|------------------------------|

Societa' : OTOFARMA

Utenza - referente : OTOFARMAESTN01 - Incarnato Bartolomucci Anna

Tipologia : REGEM

Data/Ora Ricezione : 2 Luglio 2026 08:00:11

Data/Ora Inizio Diffusione : 2 Luglio 2026 08:00:11

Oggetto : OTOFARMA JOINS THE INTERMONTE VALORE ITALIA INDEX

Testo del comunicato

Vedi allegato



Press release

OTOFARMA JOINS THE INTERMONTE VALORE ITALIA INDEX

Naples, 2 July 2026 – **Otofarma Group** – with more than 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids primarily distributed through the pharmacy channel – proudly announces that it has been selected among the 100 companies listed on the Italian Stock Exchange that make up the **Intermonte Valore Italia Index**, dedicated to SMEs with a market capitalization below €1 billion and not included in the FTSE MIB.

The Index was created with the aim of enhancing the universe of listed Italian small and medium-sized enterprises, establishing a meeting point between entrepreneurship, capital markets and the Italian economic system. It represents a snapshot of the best expertise within the Italian economy, helping to broaden and diversify investment opportunities compared with traditional indices, for both domestic and international investors.

Companies are selected according to rigorous technical and financial criteria designed to ensure adequate levels of liquidity, transparency and investability. These include minimum free float requirements, strong governance standards, analyst coverage, financial sustainability and leverage levels, as well as representativeness within the Index itself.

The Index is part of **PMI2Change**, the innovative project launched by Banca Generali on 1 July 2026 at Palazzo Mezzanotte, the headquarters of Borsa Italiana. The initiative aims to support the growth and competitiveness of Italian entrepreneurs by fostering the development of listed SMEs. PMI2Change addresses the limited liquidity and valuation of listed SMEs, helping to create more efficient conditions for matching capital with businesses.

“Joining the Intermonte Valore Italia Index represents an important recognition of Otofarma’s growth journey, transparency and financial strength built over the years. Being included among the 100 Italian SMEs selected on the basis of rigorous financial and governance criteria confirms the validity of our industrial model and our ability to create long-term value”, said **Gennaro Bartolomucci, Chairman and Chief Executive Officer of Otofarma**. “We also strongly welcome initiatives such as PMI2Change, which help increase the visibility and attractiveness of listed SMEs, fostering a more effective connection between investors and companies that represent an essential component of the Italian economy”.

The initiative leverages the expertise of Intermonte, a leading Italian financial services operator with more than 30 years of experience in capital markets, particularly in SME research, sales & trading, market making and investment banking. Intermonte has been part of the Banca Generali Group since early 2025.



Building on the Index, Banca Generali, together with Investlinx and Intermonte, has also launched a new actively managed ETF compliant with Italian PIR regulations, which will invest primarily within the universe defined by the Index. Banca Generali has committed to supporting the fund's launch with an initial fundraising target of €100 million in the first months, gradually increasing exposure to reach €500 million over the medium term. The initiative is expected to generate new investment flows of between €1 million and €2 million per day, representing more than 5% of the Index's free float.

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by CONSOB by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.

Identification Codes

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, Chairman and CEO, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A. - Investor relations

Anna Incarnato Bartolomucci

E-mail: investor.relations@otofarma.it

mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: ega@alantra.com

mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – michele.bon@secnewgate.it – +39 338 693 3868

Francesca Brambilla – francesca.brambilla@secnewgate.it – +39 338 627 2146

Fine Comunicato n.20343-18-2026

Numero di Pagine: 4